Gilead UK and Ireland Fellowship and Medical Grants Programme

Gilead accepts applications for projects and initiatives that can ultimately lead to improved awareness and diagnosis of viral hepatitis (B, C and Delta) and/or demonstrate the proof of concept/pilot Opt-Out testing of BBV (HBV, HCV, HDV and HIV)

We are interested in supporting projects that:

• Improve awareness and diagnosis of viral hepatitis (B, C, and Delta), including among migrant and other underserved communities
• Demonstrate proof of concept and/or pilot Opt-Out BBV testing across a broader range of healthcare and community settings where high prevalence rates of HIV, HCV, HDV and HBV are expected (e.g., primary care, women’s health hubs, psychiatry services, migrant health services, and services targeting underserved populations)
• Optimise linkage to care and/or management for people living with viral hepatitis (B, C, and Delta), including peer support
• Evaluate innovative approaches to optimising patient pathways and enabling rapid access to care for those newly diagnosed with viral hepatitis (B, C, and Delta)
• Enhance patient support programmes and tools for people living with viral hepatitis (B, C, and Delta), with a focus on addressing stigma, community outreach and engagement, disease awareness, and prevention of transmission
• Improve understanding of, and reduce, variations in care for people living with viral hepatitis (B, C, and Delta), and improve the experiences of people from marginalised communities
• Improve the use of data to diagnose people with viral hepatitis (B, C, and Delta) and to identify those lost to follow-up
• Assess the societal and health economic implications of hepatitis B and Delta

Gilead accepts applications for projects and initiatives (up to £50,000) that ultimately lead to an improvement in patient care within the field of CAR T-cell therapy and haemato-oncology. Projects must have a defined end date within 12 months.

This may include, but is not limited to:

• Audits assessing patient profiles, disease outcomes, access to care and treatment patterns
• Monitoring of patient-reported outcomes, quality of life measures or educational tools for patients and carers
• New infrastructure/processes established for better diagnosis or detection of disease, or prediction or monitoring of safety and efficacy outcomes to treatment
• Investigations into better detection and treatment of special patient populations and sub-types

Gilead accepts applications for projects and initiatives that support innovation and best practice sharing, with the aim of improving care and reducing inequalities in access to healthcare in the field of oncology. Priority will be given to projects focussing on breast cancer.

This may include, but is not limited to:

• Audits or registry reviews assessing patient profiles, disease outcomes and treatment patterns (but not efficacy of specific treatments)
• Setting up new infrastructure for better diagnosis or detection of disease, or prediction or monitoring of safety and efficacy outcomes to treatment including increased disease awareness in primary care and amongst members of the public
• Establishing novel patient support programmes or tools
• New protocols to facilitate improved efficiency in patient care pathways
• Frameworks to improve monitoring of patient-reported outcome measures or quality of life instruments